BioCryst (BCRX) Q4 2025 earnings review
A Transformative Year Obscures a Coming Growth Deceleration
BioCryst achieved a landmark year in 2025: retiring $323M in debt, offloading its European business, and acquiring Astria Therapeutics to complete its HAE portfolio. The Q4 headline GAAP Net Income of $245.8M is a mirage created by the $243.3M EU divestiture license revenue. The real story is the U.S. ORLADEYO engine, which generated $146.7M in Q4 (+37% YoY) and pushed Non-GAAP operating profit to a record $58.4M. However, investors must look forward: 2026 guidance implies a severe deceleration in ORLADEYO growth. Normalizing for the EU divestiture, 2026 revenue guidance of $635M at the midpoint implies ~12.7% underlying growth, a stark drop from the 43% ex-EU growth delivered in 2025.
🐂 Bull Case
Using proceeds from the European divestiture, BioCryst paid off the entirety of its Pharmakon term loan ($323.7M). This removes nearly $80M in annual interest expense, heavily de-risking the balance sheet and ensuring the U.S. commercial engine drops pure cash to the bottom line.
The Astria Therapeutics acquisition (navenibart) transforms BioCryst from a single-product company into an HAE powerhouse. Offering both the leading oral prophylactic and a late-stage, low-burden injectable allows them to leverage their highly efficient commercial infrastructure across a wider patient base.
🐻 Bear Case
ORLADEYO's U.S. growth was phenomenal in 2025 (+37% YoY in Q4), driven heavily by a massive Q1 spike in paid-patient conversions due to the Inflation Reduction Act. That was a one-time tailwind. 2026 guidance suggests underlying growth will plummet to the low teens.
The addition of navenibart's Phase 3 program will add $70M-$80M to operating expenses in 2026. If the core ORLADEYO revenue decelerates faster than expected, this new R&D burden could compress the newly found operating margins.
⚖️ Verdict: ⚪
Neutral. Management executed flawlessly on balance sheet restructuring and strategic M&A in 2025. The transition to sustained non-GAAP profitability is real. However, the guided deceleration in top-line growth means multiple expansion from here will be difficult without immediate pipeline successes.
Key Themes
Decelerating Underlying ORLADEYO Growth
BioCryst guided FY26 ORLADEYO revenue to $625M-$645M. In FY25, ex-Europe ORLADEYO revenue was $563.1M. This means the underlying core business is projected to grow by roughly 12.7% at the midpoint next year. This is a severe deceleration from the 43% ex-EU growth achieved in FY25. The low-hanging fruit of moving Medicare patients to paid drug is gone, and the company must now rely strictly on volume growth in an increasingly crowded HAE market.
Balance Sheet Transformation Yields Free Cash Flow
The execution on capital allocation was masterclass. BioCryst utilized the $243.3M from the European divestiture to eliminate the toxic $323.7M Pharmakon Term Loan. Interest expense, which drained $78.9M in 2025, will effectively vanish. With Non-GAAP operating profit at $214.2M for FY25 (+198% YoY), the company is now a cash-generating machine, unburdened by debt, capable of self-funding its clinical pipeline.
Astria Acquisition Secures the HAE Franchise
The January 2026 close of the Astria Therapeutics deal fundamentally alters BioCryst's long-term trajectory. Navenibart (a long-acting monoclonal antibody) showed 97% median HAE attack rate reduction in the ALPHA-SOLAR trial. By offering both the standard-of-care oral (ORLADEYO) and a highly efficacious long-acting injectable (navenibart), BioCryst locks down the HAE market across patient preferences, insulating it against newer entrants like garadacimab.
Pediatric Expansion Approved
In December 2025, the FDA approved ORLADEYO oral pellets for children aged 2 to <12. This unlocks a totally new demographic of approximately 500 diagnosed patients in the U.S. An oral option is incredibly sticky in pediatrics compared to injectables, providing a reliable growth driver to offset the decelerating adult base in 2026.
Pipeline Slippage: BCX17725 Delayed
Execution outside of HAE remains a concern. The BCX17725 (Netherton syndrome) program has suffered enrollment delays. Initially promised for late 2025, data from up to 12 patients is now not expected until the end of 2026. For a company attempting to pivot into a broader rare disease consolidator, clinical execution delays on early-stage assets dampen enthusiasm.
Other KPIs
R&D fell 5% YoY in 2025 due to the closeout of the Factor D program. However, this trend is Reversing. The integration of Astria Therapeutics and the enrollment of the Phase 3 ALPHA-ORBIT and ORBIT-EXPANSE trials for navenibart are expected to add $70M-$80M in OpEx in 2026.
Combined Sales & Marketing ($144.1M) and General & Administrative ($85.0M) non-GAAP expenses grew over 20% YoY. Management cites pediatric launch support and headcount growth. As U.S. revenue growth decelerates into 2026, SG&A leverage will be a key metric to monitor to ensure margins do not compress.
Guidance
Decelerating. Using the midpoint of $635M, this represents a sluggish 5.5% reported YoY growth over FY25 ($601.8M). Even when stripping out the $38.7M European revenue from the FY25 baseline, the implied underlying growth is ~12.7%, a stark drop from the 43% ex-EU growth achieved in 2025.
Reversing. Down drastically from the reported $874.8M in FY25, though FY25 was heavily inflated by the one-time $243.3M European license divestiture. The delta between ORLADEYO guidance and Total guidance implies roughly $10M-$15M in alternative revenue (mostly RAPIVAB).
Accelerating. Up from $362.1M in FY25 (Non-GAAP R&D + SG&A). This massive increase reflects the $70M-$80M burden of integrating Astria and funding the navenibart Phase 3 clinical trials, effectively eating into the operational leverage generated by the U.S. ORLADEYO business.
Key Questions
Modeling ORLADEYO's U.S. Plateau
Excluding the European divestiture, 2026 guidance implies a drop to ~12.7% growth. What portion of this is conservative posturing versus the reality of market saturation, and how much is the pediatric launch expected to contribute to that $635M midpoint?
Margin Compression in 'BioCryst 2.0'
With Non-GAAP OpEx guided up by roughly $100M YoY largely due to Astria, and ORLADEYO revenue growth decelerating, should investors expect a contraction in Non-GAAP Operating Profit in 2026, or will gross-to-net improvements offset the R&D spike?
Capital Allocation Post-Debt
Now that the $323M Pharmakon loan is completely erased and the company is generating positive cash flow, what is the strategy for the $337M in cash? Are further rare disease acquisitions imminent, or is the focus solely on executing navenibart Phase 3?